A Craigavon company has made what it claims is a major breakthrough in the treatment of colon cancer.
Scientists from Almac Pharmaceutical Development have developed a test to detect the likelihood of the cancer recurring in patients who have undergone surgery.
It allows doctors to identify high risk patients who may benefit from chemotherapy.
Almac said it could be available to patients within the next two years.
***
Almac said that, following further external validation, the test could be available to UK patients within two years, and potentially even sooner in the US.
***
more:
http://www.bbc.co.uk/news/uk-northern-ireland-15631626